Summit Therapeutics Inc. Operating Income
Summit Therapeutics Inc. (SMMT) reported Operating Income of -$226.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-24.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2025-02-24
- Summit Therapeutics Inc. operating income (loss) for the quarter ending 2024-12-31 was -$65.61M.
- Summit Therapeutics Inc. operating income (loss) for the quarter ending 2024-09-30 was -$58.38M.
- Summit Therapeutics Inc. operating income (loss) for the quarter ending 2024-06-30 was -$59.62M.
- Summit Therapeutics Inc. operating income (loss) for the quarter ending 2024-03-31 was -$42.39M.
- Summit Therapeutics Inc. operating income (loss) for fiscal 2024 was -$226.00M.
- Summit Therapeutics Inc. operating income (loss) for fiscal 2023 was -$609.65M.
- Summit Therapeutics Inc. operating income (loss) for fiscal 2022 was -$72.09M.
- Summit Therapeutics Inc. operating income (loss) for fiscal 2021 was -$86.19M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 11 month | Operating Income (Loss) 11 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | -$65.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$123.99M derived: sum of 2 quarters · filed 2025-02-24 | -$183.61M derived: sum of 3 quarters · filed 2025-02-24 | -$226.00M 10-K · filed 2025-02-24 | ||||||
| 2024-09-30 | -$58.38M 10-Q · filed 2024-10-30 | -$118.00M derived: sum of 2 quarters · filed 2024-10-30 | -$160.38M 10-Q · filed 2024-10-30 | -$196.59M derived: sum of 4 quarters · filed 2025-02-24 | ||||||
| 2024-06-30 | -$59.62M 10-Q · filed 2024-08-06 | -$102.01M 10-Q · filed 2024-08-06 | -$138.22M derived: sum of 3 quarters · filed 2025-02-24 | -$158.71M derived: sum of 4 quarters · filed 2025-02-24 | ||||||
| 2024-03-31 | -$42.39M 10-Q · filed 2024-05-01 | -$78.60M derived: sum of 2 quarters · filed 2025-02-24 | -$99.09M derived: sum of 3 quarters · filed 2025-02-24 | -$114.89M derived: sum of 4 quarters · filed 2025-02-24 | ||||||
| 2023-12-31 | -$36.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$56.70M derived: sum of 2 quarters · filed 2025-02-24 | -$72.50M derived: sum of 3 quarters · filed 2025-02-24 | -$609.65M 10-K · filed 2025-02-24 | ||||||
| 2023-09-30 | -$20.49M 10-Q · filed 2024-10-30 | -$36.29M derived: sum of 2 quarters · filed 2024-10-30 | -$573.44M 10-Q · filed 2024-10-30 | -$593.74M derived: sum of 4 quarters · filed 2025-02-24 | ||||||
| 2023-06-30 | -$15.79M 10-Q · filed 2024-08-06 | -$552.95M 10-Q · filed 2024-08-06 | -$573.25M derived: sum of 3 quarters · filed 2025-02-24 | -$590.19M derived: sum of 4 quarters · filed 2025-02-24 | ||||||
| 2023-03-31 | -$537.15M 10-Q · filed 2024-05-01 | -$557.45M derived: sum of 2 quarters · filed 2025-02-24 | -$574.39M derived: sum of 3 quarters · filed 2025-02-24 | -$587.09M derived: sum of 4 quarters · filed 2025-02-24 | ||||||
| 2022-12-31 | -$20.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$37.24M derived: sum of 2 quarters · filed 2025-02-24 | -$49.93M derived: sum of 3 quarters · filed 2025-02-24 | -$72.09M 10-K · filed 2025-02-24 | ||||||
| 2022-09-30 | -$16.94M 10-Q · filed 2023-11-07 | -$29.63M derived: sum of 2 quarters · filed 2023-11-07 | -$51.79M 10-Q · filed 2023-11-07 | -$77.84M derived: sum of 4 quarters · filed 2023-11-07 | ||||||
| 2022-06-30 | -$12.69M 10-Q · filed 2023-08-09 | -$34.85M 10-Q · filed 2023-08-09 | -$60.90M derived: sum of 3 quarters · filed 2023-08-09 | -$80.38M derived: sum of 4 quarters · filed 2023-08-09 | ||||||
| 2022-03-31 | -$22.16M 10-Q · filed 2023-05-11 | -$48.20M derived: sum of 2 quarters · filed 2023-05-11 | -$67.69M derived: sum of 3 quarters · filed 2023-05-11 | -$91.42M derived: sum of 4 quarters · filed 2023-05-11 | ||||||
| 2021-12-31 | -$26.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$45.53M derived: sum of 2 quarters · filed 2023-03-09 | -$69.26M derived: sum of 3 quarters · filed 2023-03-09 | -$86.19M 10-K · filed 2023-03-09 | ||||||
| 2021-09-30 | -$19.49M 10-Q · filed 2022-11-09 | -$43.22M derived: sum of 2 quarters · filed 2022-11-09 | -$60.14M 10-Q · filed 2022-11-09 | -$71.69M derived: sum of 4 quarters · filed 2022-12-21 | ||||||
| 2021-06-30 | -$23.73M 10-Q · filed 2022-08-11 | -$40.65M 10-Q · filed 2022-08-11 | -$52.21M derived: sum of 3 quarters · filed 2022-12-21 | -$69.15M derived: sum of 4 quarters · filed 2022-12-21 | ||||||
| 2021-03-31 | -$16.92M 10-Q · filed 2022-05-11 | -$28.48M derived: sum of 2 quarters · filed 2022-12-21 | -$45.42M derived: sum of 3 quarters · filed 2022-12-21 | -$60.78M derived: sum of 4 quarters · filed 2022-12-21 | ||||||
| 2020-12-31 | -$11.56M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | -$28.50M derived: sum of 2 quarters · filed 2022-12-21 | -$43.85M derived: sum of 3 quarters · filed 2022-12-21 | -$53.19M 10-K/A · filed 2022-12-21 | ||||||
| 2020-09-30 | -$16.94M 10-Q · filed 2021-11-15 | -$18.22M 10-Q · filed 2020-11-16 | -$32.30M derived: sum of 2 quarters · filed 2021-11-15 | -$41.64M 10-Q · filed 2021-11-15 | -$39.64M 10-Q · filed 2020-11-16 | |||||
| 2020-06-30 | -$15.36M 10-Q · filed 2021-08-12 | -$15.37M 8-K · filed 2020-09-29 | -$24.70M 10-Q · filed 2021-08-12 | -$21.43M 8-K · filed 2020-09-29 | ||||||
| 2020-03-31 | -$9.34M 10-Q · filed 2021-05-17 | |||||||||
| 2019-12-31 | -$27.47M 10-K · filed 2021-03-31 | -$28.80M 8-K · filed 2020-09-29 | ||||||||
| 2019-09-30 | -$6.19M 10-Q · filed 2020-11-16 | -$12.93M derived: sum of 2 quarters · filed 2020-11-16 | -$19.83M 10-Q · filed 2020-11-16 | |||||||
| 2019-06-30 | -$6.74M 8-K · filed 2020-09-29 | -$13.64M 8-K · filed 2020-09-29 | ||||||||
| 2019-01-31 | $5.39M 10-K · filed 2021-03-31 | $6.00M 8-K · filed 2020-09-29 | ||||||||
| 2018-01-31 | -$28.37M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |